Prescient Therapeutics granted European patent for its cancer therapy

Clinical-stage oncology company Prescient Therapeutics Ltd (ASX: PTX) is pleased to announce that a new patent has been granted in Europe providing platform technology protection for its lead clinical compound PTX-200 (triciribine phosphate).

The patent “Effective treatment of tumors and cancers with triciribine and related compounds”, issued as European patent number EP2574341, covers particular therapeutic regimens of triciribine phosphate and compositions with reduced toxicity for the treatment of tumors, and cancer.

PTX’s CEO & Managing Director Steven Yatomi-Clarke said “This is a key patent in the PTX- 200 patent estate and it is pleasing to have it granted in Europe. PTX-200 is well advanced in the clinic with Phase 1b/2 studies underway in leukemia, breast and ovarian cancers in leading US centers. This granting of this patent further consolidates PTX’s position with this promising compound.”


About Prescient Therapeutics Limited (PTX) PTX is a clinical stage oncology company developing novel compounds that show promise as potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy.

PTX’s lead drug candidate PTX-200 inhibits an important tumor survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Unlike other drug candidates that target Akt inhibition which are non-specific kinase inhibitors that have toxicity problems, PTX-200 has a novel mechanism of action that specifically inhibits Akt whilst being comparatively safer.

This highly promising compound is now the focus of three current clinical trials. The first is a Phase 1b/2 trial evaluating PTX-200 as a new therapy for relapse and refractory Acute Myeloid Leukemia, being conducted at Florida’s H. Lee Moffitt Cancer Center (Moffitt); Yale Cancer Center in New Haven, Connecticut (Yale) and Kansas University Medical Center (KUMC) under the leadership of Professor Jeffrey Lancet, MD. PTX is also conducting a Phase 2 study examining PTX-200 in breast cancer patients at the prestigious Montefiore Cancer Center in New York and the Moffitt.

The third trial is a Phase 1b/2 trial of PTX-200 in combination with current standard of care is also underway in patients with recurrent or persistent platinum resistant ovarian cancer at the Moffitt. PTX’s second novel drug candidate, PTX-100, is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase (GGT). It also blocks the Ral and Rho circuits in cancer cells which act as key oncogenic survival pathways, leading to apoptosis (death) of cancer cells. PTX-100 was well tolerated and achieved stable disease in a Phase 1 trial in advanced solid tumors.

Further enquiries:

Steven Yatomi-Clarke

CEO & Managing Director

Prescient Therapeutics Limited

+61 417 601 440